← Back to patent-cliff list
CAS 57260-71-6
tert-butyl piperazine-1-carboxylate1-Boc-piperazineN-BOC-piperazine
Codes: PALB-012, OLAP-007, VENE-015, AVAPR-002, BREX-008, CARI-002, VORT-017, MITAP-005
Physicochemical properties & identification
- Appearance
- White to off-white crystalline powder
- Melting point
- approx. 49 - 53 °C
- Solubility
- Soluble in ethanol, ethyl acetate and DCM; slightly soluble in water
- Storage
- Sealed and dry; apply standard precautions for Boc-protected amines
Applications
- · The standard building block for mono-protected piperazine: selective N-alkylation strategies for CNS drugs (cariprazine and others) and for many piperazine-containing APIs
- · A common intermediate for coupling / linker chemistry and high-throughput synthesis
Application context (from source-drug indications)
Breast cancerPalbociclibEndometrial cancerOlaparibCastration-resistant prostate cancerOlaparibProstate cancerOlaparibPeritoneal cancerOlaparibEpithelial ovarian cancerOlaparibFallopian tube cancerOlaparibAcute myeloid leukaemiaVenetoclaxChronic lymphocytic leukaemiaVenetoclaxSystemic mastocytosisAvapritinibGastrointestinal stromal tumourAvapritinibMast cell leukaemiaAvapritinibSchizophreniaBrexpiprazoleAlzheimer's diseaseBrexpiprazoleAgitationBrexpiprazoleDepressionBrexpiprazoleDepressive disorderBrexpiprazoleMajor depressive disorderBrexpiprazoleMajor depressive disorderCariprazine HydrochlorideSchizophreniaCariprazine HydrochlorideManiaCariprazine HydrochlorideMajor depressive disorderVortioxetine HydrobromidePostoperative painVortioxetine HydrobromideCannabis dependenceVortioxetine HydrobromideAnxietyVortioxetine HydrobromideAnxiety disorderVortioxetine HydrobromideDepressionVortioxetine Hydrobromideα-地中海贫血Mitapivat sulfateBeta thalassaemiaMitapivat sulfate丙酮酸激酶缺乏症Mitapivat sulfateHaemolytic anaemiaMitapivat sulfate先天性溶血性贫血Mitapivat sulfateSickle cell diseaseMitapivat sulfate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Palbociclib | Tier A — Act now | 2027 |
| Olaparib | Tier A — Act now | 2028 |
| Venetoclax | Tier B — Position early | 2030 |
| Avapritinib | Tier C — Watch / trade | 2032 |
| Brexpiprazole | Tier A — Act now | 2029 |
| Cariprazine Hydrochloride | Tier A — Act now | 2029 |
| Vortioxetine Hydrobromide | Tier B — Position early | - |
| Mitapivat sulfate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
tert-butyl piperazine-1-carboxylate→tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate→5-bromo-2,4-dichloropyrimidine→cyclopentanamine→5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine→(E)-but-2-enoic acid→2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one→6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one→tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate→tert-butyl 4-(6-((6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate→1-(vinyloxy)butane→tert-butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate→5-bromo-2-nitropyridine
3-hydroxyisobenzofuran-1(3H)-one→dimethyl phosphonate→dimethyl (3-oxo-1,3-dihydroisobenzofuran-1-yl)phosphonate→2-fluoro-5-formylbenzonitrile→(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile→2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid→tert-butyl piperazine-1-carboxylate→tert-butyl 4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazine-1-carboxylate→4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one→cyclopropanecarbonyl chloride
5-bromo-1H-pyrrolo[2,3-b]pyridine→5-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine→1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridin-5-ol→methyl 2,4-difluorobenzoate→methyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-fluorobenzoate→1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine→methyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoate→5-bromo-1H-pyrrolo[2,3-b]pyridine→5-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine→methyl 4,4-dimethyl-2-oxocyclohexane-1-carboxylate→methyl 4,4-dimethyl-2-(((trifluoromethyl)sulfonyl)oxy)cyclohex-1-ene-1-carboxylate→(4-chlorophenyl)boronic acid→methyl 4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carboxylate→(4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol→tert-butyl piperazine-1-carboxylate→tert-butyl 4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine-1-carboxylate
5-bromo-1H-pyrrolo[2,3-b]pyridine→5-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine→(4-chlorophenyl)boronic acid→tert-butyl piperazine-1-carboxylate→tert-butyl 4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine-1-carboxylate→4-bromo-2-fluoro-1-iodobenzene→VENE-018→1H-pyrrolo[2,3-b]pyridin-5-ol→tert-butyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-bromobenzoate→1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine→4-(di-tert-butylphosphanyl)-N,N-dimethylaniline→tert-butyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoate→3,3-dimethylcyclohexanone→2-chloro-4,4-dimethylcyclohex-1-ene-1-carbaldehyde→4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde
1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethan-1-amine→6-bromopyrrolo[2,1-f][1,2,4]triazin-4(3H)-one→1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole→6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one→(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethan-1-amine→ethyl 2-chloropyrimidine-5-carboxylate→tert-butyl piperazine-1-carboxylate→ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylate→2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylic acid→N,O-dimethylhydroxylamine→tert-butyl 4-(5-(methoxy(methyl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate→(4-fluorophenyl)magnesium bromide→tert-butyl 4-(5-(4-fluorobenzoyl)pyrimidin-2-yl)piperazine-1-carboxylate→(4-fluorophenyl)(2-(piperazin-1-yl)pyrimidin-5-yl)methanone hydrochloride→4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazine→(4-fluorophenyl)(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)methanone→(S)-2-methylpropane-2-sulfinamide→(Z)-N-((4-fluorophenyl)(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)methylene)-2-methylpropane-2-sulfinamide→N-(1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethyl)-2-methylpropane-2-sulfinamide
2-chloro-6-fluorobenzaldehyde→tert-butyl piperazine-1-carboxylate→tert-butyl 4-(3-chloro-2-formylphenyl)piperazine-1-carboxylate→ethyl 2-mercaptoacetate→tert-butyl 4-(2-(ethoxycarbonyl)benzo[b]thiophen-4-yl)piperazine-1-carboxylate→4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzo[b]thiophene-2-carboxylic acid→tert-butyl 4-(benzo[b]thiophen-4-yl)piperazine-1-carboxylate
1-bromo-2,3-dichlorobenzene→tert-butyl piperazine-1-carboxylate→tert-butyl 4-(2,3-dichlorophenyl)piperazine-1-carboxylate→1-(2,3-dichlorophenyl)piperazine hydrochloride→tert-butyl ((1r,4r)-4-(2-oxoethyl)cyclohexyl)carbamate→tert-butyl ((1r,4r)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)carbamate→(1r,4r)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexanamine→dimethylcarbamic chloride
1-((2-fluorophenyl)sulfinyl)-2,4-dimethylbenzene→tert-butyl piperazine-1-carboxylate→tert-butyl 4-(2-((2,4-dimethylphenyl)sulfinyl)phenyl)piperazine-1-carboxylate→1-(2-((2,4-dimethylphenyl)sulfinyl)phenyl)piperazine→2,4-dimethylbenzenethiol→1,2-difluorobenzene→(2,4-dimethylphenyl)(2-fluorophenyl)sulfane
ethyl 4-aminobenzoate→quinoline-8-sulfonyl chloride→ethyl 4-(quinoline-8-sulfonamido)benzoate→4-(quinoline-8-sulfonamido)benzoic acid→tert-butyl piperazine-1-carboxylate→tert-butyl 4-(4-(quinoline-8-sulfonamido)benzoyl)piperazine-1-carboxylate→N-(4-(piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide→cyclopropanecarbaldehyde→Mitapivat
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | Ethyl 2-chloropyrimidine-5-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 1-Methyl-4-pyrazole boronic acid pinacol ester Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-Fluoro-5-formylbenzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]benzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin -1-yl)Methyl)benzoic acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 1-(Cyclopropylcarbonyl)piperazine hydrochloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonic acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 5-broMo-2-chloro-N-cyclopentylpyriMidin-4-aMine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | Tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | PD 0332991 HCl Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | Methyl 4-Fluoro-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzoate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 3-nitro-4-((tetrahydro-2H-pyran-4-yl)MethylaMino)benzenesulfonaMide Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.